Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

Therapeutic Implications of Targeting Energy Metabolism in Breast Cancer

PPARs are ligand activated transcription factors. PPARγ agonists have been reported as a new and potentially efficacious treatment of inflammation, diabetes, obesity, cancer, AD, and schizophrenia. Since cancer cells show dysregulation of glycolysis they are potentially manageable through changes in metabolic environment. Interestingly, several of the genes involved in maintaining the metabolic...

Editorial: Cancer Metabolism: Molecular Targeting and Implications for Therapy

Targeting cancer metabolism.

The understanding that oncogenes can have profound effects on cellular metabolism and the discovery of mutations and alterations in several metabolism-related enzymes--isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2), succinate dehydrogenase (SDH), fumarate hydratase (FH), and pyruvate kinase M2 (PKM2)--has renewed interest in cancer metabolism and renewed hope of taking the...

Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.

Radiotherapy, an important treatment modality in oncology, kills cells through induction of oxidative stress. However, malignant tumors vary in their response to irradiation as a consequence of resistance mechanisms taking place at the molecular level. It is important to understand these mechanisms of radioresistance, as counteracting them may improve the efficacy of radiotherapy. In this revie...

Digoxin, HIF-1, and cancer.

In a recent issue of PNAS, Zhang et al. (1) find that digoxin inhibits HIF-1 (a transcription factor highly involved in cancer development) and suggest that this effect might be observed in patients taking this drug. They also report that digoxin blocks tumor growth in mice (1). These data suggest that digoxin has anticancer potential. The authors observe that digoxin inhibits HIF-1 at 100 nM a...